Multiple Sclerosis - The State of the Art

Explore the current state of Multiple Sclerosis (MS) diagnosis and treatment in this comprehensive 1-hour 25-minute lecture by Dr. Lucas B. Kipp from Stanford University. Delve into risk factors, including genetic and environmental influences, with a focus on modifiable factors like smoking and gut microbiome. Learn about the 2017 McDonald Diagnostic Criteria for Relapsing-Remitting MS and the importance of early diagnosis and treatment for better outcomes. Discover the goals of therapy, including the concept of No Evidence of Disease Activity (NEDA), and the use of neurofilament light chain as a biomarker. Examine diagnostic challenges, including MOG antibody testing, and the natural history of MS progression from inflammation to degeneration. Explore the 15 FDA-approved treatments for Relapsing-Remitting MS and the single approved treatment for Primary Progressive MS. Gain insights into ongoing research in progressive MS, therapies supporting mitochondrial function, and the potential of stem cell therapy in MS treatment.

Intro
Disclosures
Risk Factors - Genetic
Risk Factors - Environmental
Modifiable Risk Factors - Smoking
Modifiable Risk Factors - Gut Microbiome
2017 McDonald Diagnostic Criteria - RRMS
Earlier Diagnosis = Earlier Treatment
Earlier Treatment = Better Outcomes
Goals of Therapy/Monitoring - NEDA
Neurofilament light chain (NFL)
Diagnostic Challenges
Diagnostic Accuracy - MOG antibody
Natural Hx - Inflammation to Degeneration
15 FDA Approved Treatments for RRMS
Better Therapies = Better Outcomes
1 FDA Approved Treatment for PPMS
Progressive MS Research
Therapies Support Mitochondria
Stem Cell Therapy